2024-11-13 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a global pharmaceutical company that develops and manufactures medicines and vaccines. Its cumulative return is 7.35%, significantly lagging behind the S&P 500 (VOO) with a cumulative return of 179.25%. This results in a negative divergence of -171.9, which is in the 35th percentile of historical divergence, indicating that PFE has underperformed the S&P 500 for most of its historical period. 

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.9% | 17.4% | -9.5% | 0.8 | 194.7 |
| 2016-2018  | 52.6% | 17.4% | 20.3% | 0.8 | 234.7 |
| 2017-2019  | 32.5% | 21.8% | -19.2% | 0.8 | 210.7 |
| 2018-2020  | 19.0% | 31.4% | -28.3% | 0.7 | 208.6 |
| 2019-2021  | 61.4% | 31.4% | -38.6% | 0.6 | 334.6 |
| 2020-2022  | 54.1% | 28.6% | 30.5% | 0.6 | 290.4 |
| 2021-2023  | -12.3% | 47.0% | -47.2% | 0.4 | 163.2 |
| 2022-2024  | -47.0% | 44.6% | -77.4% | 0.5 | 148.7 |

**2. Recent Price Movement:**

* Closing price: 26.19 
* 5-day moving average: 26.63
* 20-day moving average: 27.82
* 60-day moving average: 28.38

The current price is below all three moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* RSI: 20.71 (oversold)
* PPO: -0.69 (bearish)
* Delta_Previous_Relative_Divergence: -1.33 (short-term downtrend)
* Expected Return: 0.0% (long-term potential for outperformance vs. S&P 500) 

The RSI indicates that the stock is currently oversold, suggesting a potential rebound. However, the PPO is bearish and the recent relative divergence further suggests that the downtrend might continue. 

**4. Recent Earnings and Outlook:**

| Date       | EPS | Expected EPS |
|------------|------|------|
| 2024-10-29 | 1.06 | 0.614 |
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |

Pfizer's recent earnings have exceeded expectations in the last two quarters (Q2 and Q3 2024), suggesting positive momentum. The company's ability to exceed expectations despite a challenging economic environment demonstrates resilience.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $17.70B | 70.27% |
| 2024-06-30 | $13.28B | 75.16% |
| 2024-03-31 | $14.88B | 77.29% |
| 2023-12-31 | $14.25B | 46.92% |
| 2023-09-30 | $13.49B | 31.30% |

Pfizer's revenue has been consistent and its profit margin has been healthy. The company's profitability has improved in recent quarters, likely due to strong sales of COVID-19 vaccines and treatments. 

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $92.29B | 4.84% |
| 2024-06-30 | $87.70B | 0.05% |
| 2024-03-31 | $92.28B | 3.38% |
| 2023-12-31 | $89.01B | -3.78% |
| 2023-09-30 | $96.93B | -2.46% |

Pfizer's ROE has been fluctuating but generally improving, reflecting its commitment to shareholder value creation. The company's robust equity position suggests a strong financial foundation.

**6. News and Recent Issues:**

* **Earnings News (Shacksnews):** 
  * PFE recently released a strong Q3 2024 earnings report that exceeded analysts' expectations, driven by continued strength in its COVID-19 vaccines and treatments.
  *  Earnings call transcripts and analysis highlight the company's focus on long-term growth and diversification beyond COVID-19.
  *  Investors will be watching for updates on PFE's pipeline of new drugs and its growth strategy in the upcoming earnings calls.

* **Recent Market Outlook:**
    * Despite the short-term downtrend, analysts remain optimistic about PFE's long-term prospects, particularly in the field of oncology and rare diseases.
    * PFE's strong financial position, consistent revenue growth, and pipeline of promising new drugs are cited as key growth drivers.

* **Analyst Opinions and Performance Highlights (Finbold):** 
    * According to analysts, PFE's stock is currently considered a "buy" with a consensus price target of $40. 
    * The company's strong performance in recent quarters and its robust pipeline of new drugs are cited as key factors supporting this bullish sentiment.

**7. Comprehensive Analysis:**

Pfizer Inc. (PFE) is a large-cap pharmaceutical company with a strong financial foundation and a robust pipeline of new drugs. Despite its recent underperformance compared to the S&P 500, the company's solid earnings performance, robust financial position, and promising pipeline of new drugs suggest potential for long-term growth.  The stock is currently oversold and could be considered for a long-term investment by those seeking a diversified portfolio with potential for outperformance over the market. 

**Please note:** This analysis is based on publicly available information and does not constitute investment advice. Always consult with a qualified financial professional before making any investment decisions. 
